Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dapagliflozin Alliance Targets Surging Indian Diabetes Market

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca has struck an agreement with India’s Sun Pharma under which the two companies will promote and distribute the UK-based firm’s diabetes drug dapagliflozin under different brand names. The deal means AstraZeneca can benefit from Sun’s wide distribution network to penetrate India’s rapidly growing diabetes sector while retaining intellectual property rights.


Related Content

Lilly Plans Raft Of India Launches After Trulicity Success


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts